EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- Fostair 100/6 inhalation solution
- Epanutin capsules 25, 50 and 100mg
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- FemSeven Conti
- Epanutin 300mg hard capsules
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Phenergan Injection
- Rivotril 0.5 mg and 2 mgTablets
- Rivotril Ampoules
- RELPAX 20mg and 40mg Film-Coated Tablets
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 750 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 10mg Capsules
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- VALTREX Tablets 250mg
- Vesicare 5mg & 10mg film-coated tablets
- Zomig 5mg Nasal Spray
- Water for Injections
- Tizanidine 2mg Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 10 mg hard capsules
- Orfadin 2 mg hard capsules
- Natecal D3 Chewable Tablets
Prostate Cancer
Please note - The EPG Prostate Cancer Knowledge Centre is for Doctors and other Healthcare Professionals. Enter the Prostate Cancer Knowledge Centre.
This site has been designed to provide an overview of prostate cancer for primary care physicians and other non-specialist healthcare professionals involved in the management of patients with prostate malignancies. Amongst the topics covered, the Knowledge Centre includes an up-to-date summary of the epidemiology and classification, detection and management of this prevalent neoplasm, with a particular focus on hormonal therapy...
Urology specialists are directed to the resources section, which contains links to sources of further information
Globally, at least 605,000 people are diagnosed with prostate cancer each year. The regional incidence of prostate cancer varies widely, with some of the highest rates observed in Northern and Western Europe, North America, Australia and New Zealand. In Europe, prostate cancer is the most frequently diagnosed non-cutaneous malignancy in men, accounting for one in five male cancers. Overall, 345,900 new cases were identified in 2006 in Europe alone.
Despite its prevalence, prostate cancer is only the third leading cause of cancer death in European men, causing around 87,000 deaths per year.
Figures taken from a worldwide study show that most men don't die from prostate cancer and a major current challenge is to identify those patients who will benefit from therapy.
The epidemiology of prostate cancer has been significantly affected by the widespread introduction of prostate-specific antigen (PSA) screening. By facilitating the detection of asymptomatic cancers, this test has prompted a surge in incidence rates and an increase in survival which is suggested is due to the detection of tumours at an earlier stage. Patient information on this topic can be found at Unitedagainstprostatecancer.com.
Enter the Prostate Cancer Knowledge Centre
What’s in the Prostate Cancer Knowledge Centre?
- Prostap SR DCS
... i) Metastatic prostate cancer. (ii) Locally advanced prostate cancer , as an alternative to surgical castration. (iii) As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer. (iv) As an adjuvant treatment to radical prostatectomy in patients ... - Decapeptyl SR 11.25mg
... with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration. Treatment of metastatic prostate cancer. As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer. Treatment of endometriosis. Treatment of ... - Decapeptyl SR 3mg
... with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration. Treatment of metastatic prostate cancer. As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer. Treatment of endometriosis. Treatment of uterine ... - CASODEX 150mg Film-coated Tablets
... prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression. Casodex 150 mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is ... - Prolia
... reduces the risk of vertebral, non vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures ... - Jevtana
JEVTANA in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen ...
